Smeenk F W, Klinkhamer P J, Breed W, Jansz A R, Jansveld C A
Afd. Longziekten, Catharina Ziekenhuis, Eindhoven.
Ned Tijdschr Geneeskd. 1996 Jan 13;140(2):94-8.
In four patients, men of 64, 66 and 69 years old and a woman of 65 years, who suffered from chronic obstructive pulmonary disease (COPD) and used inhalation corticosteroids in a relatively high dose (800-1600 micrograms of budesonide per day), a pulmonary infection was diagnosed caused by Mycobacterium malmoense (the first two patients) and Aspergillus (the other two) respectively. Inhalation corticosteroids are of great importance in the treatment of asthmatic patients. Their place in the treatment of patients with COPD is much less clear. The patients did not have an immunological deficiency or anatomical pulmonary or bronchial deformation which could have explained the occurrence of these infections. The high dosages of inhalation corticosteroids may have been involved in the cause of these infections by suppressing the T-cell response locally. In view of this, longterm inhalation corticosteroid treatment should be prescribed in COPD patients only if the efficacy of the medication has been proved in the individual patient involved.
在4例患者中,3名64、66和69岁的男性以及1名65岁的女性,均患有慢性阻塞性肺疾病(COPD)且使用相对高剂量的吸入性糖皮质激素(每天800 - 1600微克布地奈德),分别诊断出由马尔默分枝杆菌(前两名患者)和曲霉菌(另外两名患者)引起的肺部感染。吸入性糖皮质激素在哮喘患者的治疗中非常重要。它们在COPD患者治疗中的地位则不太明确。这些患者没有免疫缺陷或肺部或支气管的解剖学变形,而这些本可以解释这些感染的发生。高剂量的吸入性糖皮质激素可能通过局部抑制T细胞反应而参与了这些感染的病因。鉴于此,只有在已证明对相关个体患者用药有效的情况下,才应给COPD患者开长期吸入性糖皮质激素治疗的处方。